Uterine serous carcinoma: A comparison of therapy for advanced-stage disease

International Journal of Gynecological Cancer

Volumn 14, Issue 3, 2004, Pages 515-520

  Gehrig, Paolo A ^a   Morris, D E ^a   Van Le, L ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy; Paclitaxel; Platinum based chemotherapy; Uterine serous carcinoma

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL; PLATINUM DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; POSTOPERATIVE CARE; PRIORITY JOURNAL; SURVIVAL RATE; UTERINE SEROUS CARCINOMA; UTERUS CARCINOMA;

AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; CYSTADENOCARCINOMA, SEROUS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MEDICAL RECORDS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NORTH CAROLINA; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; UTERINE NEOPLASMS;

EID: 2942590754     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1048-891x.2004.14313.x     Document Type: Article

References (26)

1. Gehrig PA, Groben PA, Fowler WC, Walton LA, Van Le L. Noninvasive papillary serous carcinoma of the endometrium. Obstet Gynecol 2001;97:153-7.
2. Carcangiu ML, Chambers JT. Uterine papillary serous carcinoma: a study on 108 cases with emphasis on the prognostic significance of associated endometrioid carcinoma, absence of invasion and concomitant ovarian carcinoma. Gynecol Oncol 1992;47:298-305.
3. Nicklin JL, Copeland LJ. Endometrial papillary serous carcinoma: patterns of spread and treatment. Clin Obstet Gynecol 1996;39:686-95.
4. Creasman W, Odicino F, Maisonneuve P et al. Carcinoma of the corpus uteri. J Epidemiol Biostat 1998;3:35-61.
5. Zanotti KM, Belinson JL, Kennedy AW, Webster KD, Markman M. The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma. Gynecol Oncol 1999;74:272-7.
6. Gitsch G, Friedlander ML, Wain GV, Hacker NF. Uterine papillary serous carcinoma - a clinical study. Cancer 1995;75:2239-43.
7. Price FV, Chambers SK, Carcangui ML et al. Intravenous cisplatin, coxorubicin and cyclophosphamide in the treatment of uterine papillary serous carcinoma (UPSC). Gynecol Oncol 1993;51:383-9.
8. Chambers JT, Merino M, Kohorn EI, Peschel RE, Schwartz PE. Uterine papillary serous carcinoma. Obstet Gynecol 1987;69:109-13.
9. Grice J, Ek M, Greer B et al. Uterine papillary serous carcinoma: evaluation of long-term survival in surgically staged patients. Gynecol Oncol 1998;69:69-73.
10. Craighead PS, Sait K, Stuart GC et al. Management of aggressive histologic variants of endometrial carcinoma at the Tom Baker Cancer Center between 1984 and 1994. Gynecol Oncol 2000;77:248-53.
11. Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R. Uterine papillary serous carcinoma - A highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 1982;6:93-108.
12. Abramovich D, Markman M, Kennedy A, Webster K, Belinson J. Serum CA-125 as a marker of disease activity in uterine papillary serous carcinoma. J Cancer Res Clin Oncol 1999;125:697-8.
13. Levenback C, Burke TW, Silva E et al. Uterine papillary serous carcinoma (UPSC) treated with cisplatin, doxorubicin, and cyclophosphamide (PAC). Gynecol Oncol 1992;46:317-21.
14. Goff BA, Kato D, Schmidt RA et al. Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol 1994;54:264-8.
15. Le TD, Yamada D, Rutgers JL, DiSaia PJ. Complete response of a stage IV uterine papillary serous carcinoma to neoadjuvant chemotherapy with taxol and carboplatin. Gynecol Oncol 1999;73:461-3.
16. Resnick E, Taxy JB. Neoadjuvant chemotherapy in uterine papillary serous carcinoma. Gynecol Oncol 1996; 62:123-7.
17. Chambers JT, Chambers SK, Kohorn EI, Carcangiu ML, Schwartz PE. Uterine papillary serous carcinoma treated with intraperitoneal cisplatin and intravenous doxorubicin and cyclophosphamide. Gynecol Oncol 1996;60: 438-42.
18. Christman JE, Kapp DS, Hendrickson MR, Howes AE, Ballon SC. Therapeutic approaches to uterine papillary serous carcinoma: a preliminary report. Gynecol Oncol 1987;26:228-35.
19. Fitzgerald D, Rosenthal S. Uterine papillary serous carcinoma. Complete response to combination chemotherapy. Cancer 1985;56:1023-4.
20. Gallion HH, van Nagell JR, Powell DF et al. Stage I serous papillary carcinoma of the endometrium. Cancer 1989;63:2224-8.
21. Mallipeddi P, Kapp DS, Teng NN. Long-term survival with adjuvant whole abdominopelvic irradiation for uterine papillary serous carcinoma. Cancer 1995;71: 3076-81.
22. Frank AH, Tseng PC, Haffty BG et al. Adjuvant whole-abdominal radiation therapy in uterine papillary serous carcinoma. Cancer 1991;68:1516-9.
23. Axelrod JH, Roy T, Kimg M. A phase II study of the treatment of stage III and IV disease of advanced endometrial carcinoma and all stages of papillary serous carcinoma and clear cell carcinoma of the endometrium with total abdominal radiation therapy. SGO 1995; 56:109-44.
24. Randall ME, Brunetto G, Muss H et al. Whole abdominal radiotherapy versus combination doxorubicin-cisplatin chemotherapy in advanced endometrial carcinoma: a randomized phase III trial of the Gynecologic Oncology Group. Proc ASCO 2003;22:2.
25. Schray MF, Martinez A, Howes AE. Toxicity of open-field whole abdomen irradiation as primary post-operative treatment in gynecologic malignancy. Int J Radiat Oncol Biol Phys 1989;16:397-403.
26. Bancher-Todesca D, Neuneufel W, Williams KE et al. Influence of postoperative treatment on survival in patients with uterine papillary serous carcinoma. Gynecol Oncol 1998;71:344-7.